JOINT FILING AGREEMENT
EXHIBIT
1
This Joint Filing
Agreement dated February 14, 2017 is by and between Camber Capital
Management LLC, a Massachusetts limited liability company, and
Xxxxxxx XxXxxx, an individual (the foregoing are collectively
referred to herein as the "Filers"). Each of the Filers may be
required to file with the United States Securities and Exchange
Commission a statement on Schedule 13G with respect to common
shares, $0.001 par value of Protalix BioTherapeutics, Inc.
beneficially owned by them from time to time. Pursuant to and in
accordance with Rule 13(d)(1)(k) promulgated under the Securities
Exchange Act of 1934, as amended, the Filers hereby agree to file a
single statement on Schedule 13D and/or 13G (and any amendments
thereto) on behalf of each of such parties, and hereby further
agree to file this Joint Filing Agreement as an exhibit to such
statement, as required by such rule. This Joint Filing Agreement
may be terminated by any of the Filers upon one week's prior
written notice or such lesser period of notice as the Filers may
mutually agree.
Executed and
delivered as of the date first above written.
By: /s/ Xxxx
Xxxxxx
Xxxx
Xxxxxx
Chief Financial
Officer
XXXXXXX
XXXXXX
By: /s/ Xxxxxxx
XxXxxx
